Pregnancy-related issues in women with systemic lupus erythematosus

Abha G. Singh, Vaidehi R. Chowdhary

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

While fertility is preserved in females with systemic lupus erythematosus (SLE), it is well established that pregnancy in these patients is associated with adverse maternal and fetal outcomes, including pregnancy loss, pre-eclampsia, preterm delivery and intrauterine growth retardation, as well as neonatal mortality. Mechanisms underlying these adverse outcomes are poorly understood, and better understanding of these would allow development of targeted and personalized treatment strategies. Established risk factors for adverse pregnancy outcomes include active disease within 6 months prior to conception and during pregnancy, active nephritis, maternal hypertension, antiphospholipid antibodies and hypocomplementemia. While intensive monitoring is recommended, the comparative effectiveness of appropriate management strategies is unclear. While current strategies are able to achieve live births in 85-90% of pregnancies, certain aspects such as prevention of preterm birth, treatment of congenital heart block due to neonatal lupus and recurrent pregnancy loss despite best management, remains challenging. Pregnancy is also associated with an increased risk of flare of lupus, particularly in patients with active disease at time of conception or within 6 months prior to conception. Pregnant patients with SLE should be followed in a high-risk obstetric clinic, and care should be closely coordinated between the obstetrician and rheumatologist.

Original languageEnglish (US)
Pages (from-to)172-181
Number of pages10
JournalInternational Journal of Rheumatic Diseases
Volume18
Issue number2
DOIs
StatePublished - Feb 1 2015

Fingerprint

Systemic Lupus Erythematosus
Pregnancy
Pregnancy Outcome
Mothers
Antiphospholipid Antibodies
Fetal Growth Retardation
Nephritis
Premature Birth
Live Birth
Infant Mortality
Pre-Eclampsia
Obstetrics
Fertility
Hypertension
Therapeutics

Keywords

  • Miscellaneous topics
  • Systemic lupus erythematous

ASJC Scopus subject areas

  • Rheumatology

Cite this

Pregnancy-related issues in women with systemic lupus erythematosus. / Singh, Abha G.; Chowdhary, Vaidehi R.

In: International Journal of Rheumatic Diseases, Vol. 18, No. 2, 01.02.2015, p. 172-181.

Research output: Contribution to journalArticle

Singh, Abha G. ; Chowdhary, Vaidehi R. / Pregnancy-related issues in women with systemic lupus erythematosus. In: International Journal of Rheumatic Diseases. 2015 ; Vol. 18, No. 2. pp. 172-181.
@article{dc0c1fa9b1984c39a1d2a0e9d4fabb79,
title = "Pregnancy-related issues in women with systemic lupus erythematosus",
abstract = "While fertility is preserved in females with systemic lupus erythematosus (SLE), it is well established that pregnancy in these patients is associated with adverse maternal and fetal outcomes, including pregnancy loss, pre-eclampsia, preterm delivery and intrauterine growth retardation, as well as neonatal mortality. Mechanisms underlying these adverse outcomes are poorly understood, and better understanding of these would allow development of targeted and personalized treatment strategies. Established risk factors for adverse pregnancy outcomes include active disease within 6 months prior to conception and during pregnancy, active nephritis, maternal hypertension, antiphospholipid antibodies and hypocomplementemia. While intensive monitoring is recommended, the comparative effectiveness of appropriate management strategies is unclear. While current strategies are able to achieve live births in 85-90{\%} of pregnancies, certain aspects such as prevention of preterm birth, treatment of congenital heart block due to neonatal lupus and recurrent pregnancy loss despite best management, remains challenging. Pregnancy is also associated with an increased risk of flare of lupus, particularly in patients with active disease at time of conception or within 6 months prior to conception. Pregnant patients with SLE should be followed in a high-risk obstetric clinic, and care should be closely coordinated between the obstetrician and rheumatologist.",
keywords = "Miscellaneous topics, Systemic lupus erythematous",
author = "Singh, {Abha G.} and Chowdhary, {Vaidehi R.}",
year = "2015",
month = "2",
day = "1",
doi = "10.1111/1756-185X.12524",
language = "English (US)",
volume = "18",
pages = "172--181",
journal = "International Journal of Rheumatic Diseases",
issn = "1756-1841",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Pregnancy-related issues in women with systemic lupus erythematosus

AU - Singh, Abha G.

AU - Chowdhary, Vaidehi R.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - While fertility is preserved in females with systemic lupus erythematosus (SLE), it is well established that pregnancy in these patients is associated with adverse maternal and fetal outcomes, including pregnancy loss, pre-eclampsia, preterm delivery and intrauterine growth retardation, as well as neonatal mortality. Mechanisms underlying these adverse outcomes are poorly understood, and better understanding of these would allow development of targeted and personalized treatment strategies. Established risk factors for adverse pregnancy outcomes include active disease within 6 months prior to conception and during pregnancy, active nephritis, maternal hypertension, antiphospholipid antibodies and hypocomplementemia. While intensive monitoring is recommended, the comparative effectiveness of appropriate management strategies is unclear. While current strategies are able to achieve live births in 85-90% of pregnancies, certain aspects such as prevention of preterm birth, treatment of congenital heart block due to neonatal lupus and recurrent pregnancy loss despite best management, remains challenging. Pregnancy is also associated with an increased risk of flare of lupus, particularly in patients with active disease at time of conception or within 6 months prior to conception. Pregnant patients with SLE should be followed in a high-risk obstetric clinic, and care should be closely coordinated between the obstetrician and rheumatologist.

AB - While fertility is preserved in females with systemic lupus erythematosus (SLE), it is well established that pregnancy in these patients is associated with adverse maternal and fetal outcomes, including pregnancy loss, pre-eclampsia, preterm delivery and intrauterine growth retardation, as well as neonatal mortality. Mechanisms underlying these adverse outcomes are poorly understood, and better understanding of these would allow development of targeted and personalized treatment strategies. Established risk factors for adverse pregnancy outcomes include active disease within 6 months prior to conception and during pregnancy, active nephritis, maternal hypertension, antiphospholipid antibodies and hypocomplementemia. While intensive monitoring is recommended, the comparative effectiveness of appropriate management strategies is unclear. While current strategies are able to achieve live births in 85-90% of pregnancies, certain aspects such as prevention of preterm birth, treatment of congenital heart block due to neonatal lupus and recurrent pregnancy loss despite best management, remains challenging. Pregnancy is also associated with an increased risk of flare of lupus, particularly in patients with active disease at time of conception or within 6 months prior to conception. Pregnant patients with SLE should be followed in a high-risk obstetric clinic, and care should be closely coordinated between the obstetrician and rheumatologist.

KW - Miscellaneous topics

KW - Systemic lupus erythematous

UR - http://www.scopus.com/inward/record.url?scp=84927909487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927909487&partnerID=8YFLogxK

U2 - 10.1111/1756-185X.12524

DO - 10.1111/1756-185X.12524

M3 - Article

C2 - 25545844

AN - SCOPUS:84927909487

VL - 18

SP - 172

EP - 181

JO - International Journal of Rheumatic Diseases

JF - International Journal of Rheumatic Diseases

SN - 1756-1841

IS - 2

ER -